Behavioral interventions to reduce inappropriate antibiotic prescribing: a randomized pilot trial

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Persell, S. D., J. N. Doctor, M. W. Friedberg, D. Meeker, E. Friesema, A. Cooper, A. Haryani, et al. 2016. “Behavioral interventions to reduce inappropriate antibiotic prescribing: a randomized pilot trial.” BMC Infectious Diseases 16 (1): 373. doi:10.1186/s12879-016-1715-8. http://dx.doi.org/10.1186/s12879-016-1715-8.

Published Version
doi:10.1186/s12879-016-1715-8

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002525

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Behavioral interventions to reduce inappropriate antibiotic prescribing: a randomized pilot trial

Stephen D. Persell1,2*, Jason N. Doctor3, Mark W. Friedberg4,5, Daniella Meeker3,6, Elisha Friesema1,2, Andrew Cooper1, Ajay Haryani1, Dyanna L. Gregory1, Craig R. Fox7, Noah J. Goldstein7 and Jeffrey A. Linder4

Abstract

Background: Clinicians frequently prescribe antibiotics inappropriately for acute respiratory infections (ARIs). Our objective was to test information technology-enabled behavioral interventions to reduce inappropriate antibiotic prescribing for ARIs in a randomized controlled pilot test trial.

Methods: Primary care clinicians were randomized in a 2 × 2 × 2 factorial experiment with 3 interventions: 1) Accountable Justifications; 2) Suggested Alternatives; and 3) Peer Comparison. Beforehand, participants completed an educational module. Measures included: rates of antibiotic prescribing for: non-antibiotic-appropriate ARI diagnoses, acute sinusitis/pharyngitis, all other diagnoses/symptoms of respiratory infection, and all three ARI categories combined.

Results: We examined 3,276 visits in the pre-intervention year and 3,099 in the intervention year. The antibiotic prescribing rate fell for non-antibiotic-appropriate ARIs (24.7 % in the pre-intervention year to 5.2 % in the intervention year); sinusitis/pharyngitis (50.3 to 44.7 %); all other diagnoses/symptoms of respiratory infection (40.2 to 25.3 %); and all categories combined (38.7 to 24.2 %; all  \( p < 0.001 \)). There were no significant relationships between any intervention and antibiotic prescribing for non-antibiotic-appropriate ARI diagnoses or sinusitis/pharyngitis. Suggested Alternatives was associated with reduced antibiotic prescribing for other diagnoses or symptoms of respiratory infection (odds ratio [OR], 0.62; 95 % confidence interval [CI], 0.44–0.89) and for all ARI categories combined (OR, 0.72; 95 % CI, 0.54–0.96). Peer Comparison was associated with reduced prescribing for all ARI categories combined (OR, 0.73; 95 % CI, 0.53–0.995).

Conclusions: We observed large reductions in antibiotic prescribing regardless of whether or not study participants received an intervention, suggesting an overriding Hawthorne effect or possibly clinician-to-clinician contamination. Low baseline inappropriate prescribing may have led to floor effects.

Trial Registration: ClinicalTrials.gov: NCT01454960.

Keywords: Antibiotics, Acute respiratory infections, Behavioral economics, Social psychology, Clinical decision support

* Correspondence: spersell@nm.org

1Division of General Internal Medicine and Geriatrics, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL 60611, USA
2Center for Primary Care Innovation, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL 60611, USA

Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Viruses cause the vast majority of acute respiratory infections (ARIs), yet antibiotics remain widely prescribed [1–3]. Inappropriate antibiotic use may lead to adverse drug events, greater cost, and the spread of resistant organisms [4–6].

Interventions to reduce antimicrobial prescribing such as physician and patient education, physician audit and feedback, clinical decision support and financial or regulatory incentives have been modestly effective at reducing inappropriate antibiotic prescribing, generally producing approximately 10 % reductions in antibiotic prescribing rates [7–9]. Educational interventions may have limited impact on prescribing rates when lack of guideline awareness is not the primary reason for inappropriate antibiotic prescribing [10].

Recognizing the limitations of educational and informational interventions, we developed several interventions that draw on insights from behavioral economics and social psychology [11]. These are designed to appeal to clinician self-image and social motivation. Our interventions take into account a growing body of research indicating that individuals’ cognitive limitations and social motivations often give rise to systematic biases that violate standards of rational behavior [12–15]. Here we report the findings of a single-site clinician-randomized controlled trial that was performed in preparation for a larger multi-site trial [16].

Methods
Objectives
The objective of the study was to pilot test three interventions to improve guideline-concordant antibiotic prescribing as a precursor to inform development of a larger national cluster randomized trial (ClinicalTrials.gov Identifier: NCT01454947) [11]. The Northwestern Medical Faculty Foundation (NMFF) General Internal Medicine clinic was selected as the pilot site prior to a larger trial conducted in three other organizations for two reasons: first, the NMFF site, with a single clinic, could not accommodate a cluster-randomized trial (with randomization at the clinic level); second, the NMFF site was able to start the trial earlier than the other sites, which permitted pilot testing of the chosen interventions and optimization of study procedures.

The institutional review boards of Northwestern University and the University of Southern California approved the study. The trial registration identifier is NCT01454960 at ClinicalTrials.gov. The study protocol is available from the corresponding author by request.

Setting and participants
The NMFF General Internal Medicine clinic is a large adult primary care practice affiliated with an academic medical center and located in Chicago, Illinois. The practice uses the EpicCare electronic health record (EHR; Epic Systems Corp., Verona, WI) for all clinical documentation and for all prescribing. All attending physicians and nurse practitioners were eligible for recruitment (excluding SDP, a study investigator). Clinicians provided written informed consent before randomization. Payment for study participation was up to $300 per clinician per month of participation, regardless of intervention assignment (clinicians with less than full-time clinic work schedules were paid proportionally less). De-identified data from qualifying patient visits that occurred with enrolled clinicians were used in the analyses with an institutional review board waiver of consent.

Baseline survey and education
On enrollment, we asked all participating clinicians to complete a 15 to 20 min online survey that included questions about attitudes regarding antibiotic prescribing and an educational module containing information about ARI treatment guidelines [17–20]. The module also described the interventions to which the clinician was assigned, including changes they would observe in their EHR (for Accountable Justifications and Suggested Alternatives interventions) and examples of the kinds of emails they would receive (Peer Comparison). Brief descriptions of the interventions are provided below; details are available elsewhere [11].

Interventions
Accountable justifications intervention
Clinicians randomized to “Accountable Justifications” received EHR alerts in the course of e-prescribing an antibiotic for an ARI diagnosis (listed in the Additional file 1: Table S1). The alert briefly summarized the treatment guidelines corresponding to the ARI diagnosis for which the antibiotic was being written (e.g., “antibiotics are not indicated for non-specific upper respiratory infections”), prompted the clinician to enter a free-text justification for prescribing an antibiotic, and informed the clinician that the free-text justification provided would be included in the patient’s medical record where it would be visible to other clinicians. Clinicians were also informed that if no free-text justification was entered, a default statement “No justification for prescribing antibiotics was given” would appear in the record. If the antibiotic order was canceled, no justification was required, and no default text appeared.

These alerts were suppressed for patients whose EHR problem lists contained comorbid chronic conditions that exempted these patients from clinical guidelines (e.g. chronic obstructive pulmonary disease, heart failure, cirrhosis). The lists of diagnoses we used to suppress study-related clinical decision support were similar to...
those published in the supplement to the article describing the methods for the multi-site study [11].

This intervention draws from prior studies that show accountability improves decision making accuracy, and that public justification engenders reputational concerns. We expected that the potential to have their non-guideline-concordant choices displayed to others would make clinicians more likely to act in accordance with injunctive norms (guideline recommendations) [21–26].

**Suggested alternatives intervention**

When clinicians assigned to the Suggested Alternatives intervention entered an ARI diagnosis for a patient visit, a computerized alert presented an order set containing multiple non-antibiotic prescription and non-prescription medication choices as well as educational materials that could be printed and given to the patient [11]. We designed these order sets to include many of the most common non-antibiotic treatments used to treat ARI symptoms. This intervention draws from the behavioral insight that the presentation of (non-antibiotic) alternatives may lead clinicians to infer that these suggestions ought to be considered and this will lead to a reduced chance that an antibiotic will be prescribed [27].

**Peer comparison intervention**

Clinicians in the Peer Comparison Intervention group received emailed monthly performance feedback reports. These reports included the clinician’s individual antibiotic prescribing rates for non-antibiotic-appropriate ARIs and as a benchmark, the antibiotic prescribing rate for clinicians who were at the 10th percentile within the clinic (i.e., those with the lowest rates of inappropriate antibiotic prescribing). These rates were calculated based on the most recent 20 eligible visits excluding encounters occurring with patients who had certain comorbidities or other diagnosed bacterial infections [11].

If clinicians were among the 10 % of their peers with the “best” —i.e. lowest— prescribing rates the emailed reports told clinicians “You are a top performer.” If clinicians were not among the 10 % best, the emailed report told clinicians “You are not a top performer. You are prescribing too many unnecessary antibiotics.” The proportion of “Top Performers” could be greater than 10 % of clinicians if more than 10 % of clinicians had an inappropriate antibiotic prescribing rate of zero.

These peer comparisons were designed to differ from traditional audit and feedback by showing comparisons to top-performing instead of average-performing peers, and its delivery of positive reinforcement to current top-performers. This strategy has been previously shown to help sustain high performance [28–30].

**Experimental design and randomization**

We performed a 2 × 2 × 2 factorial randomized trial, with one arm for each possible combination of the three interventions, corresponding to the eight rows shown in Table 2. We randomized all clinicians at once in two blocks by number of qualifying visits in the prior year to ensure relatively balanced allocation, then assigned each to an intervention group using a random number generator in SAS 9.3 (SAS Institute Inc., Cary, NC) performed by a researcher who was not aware of clinicians’ identities until after the randomization was completed [31]. Once the intervention began, participating clinicians were not blinded to their study group assignments. Outcome data was collected and assessed automatically (with no human judgement) by applying identical criteria to data collected using Structured Query Language applied to EHR data.

**Measures**

We measured physician and nurse practitioner characteristics during the initial online survey. We obtained patient age, sex and race/ethnicity from EHR data.

**Primary outcome**

The primary study outcome was the rate of oral antibiotic prescribing during eligible study visits with non-antibiotic-appropriate ARI diagnoses (listed Additional file 1: Table S1). An office visit was eligible for inclusion in the outcome denominator if: 1) the patient was 18 years old or older, 2) the clinician was enrolled in the study, 3) the visit occurred during the 12-month intervention period from February 2012 through January, 2013, and 4) the patient did not have a visit with an ARI diagnosis in the prior 30 days. We excluded visits from the primary analysis when: 1) patients had certain medical co-morbidities that make ARI guidelines less likely to apply; 2) patients had concomitant visit diagnoses indicating a possible non-ARI bacterial infection or reason for antibiotic prescribing; or 3) patients had concomitant visit diagnoses indicating potentially antibiotic-appropriate ARI diagnoses or other ARI diagnoses suggestive of a bacterial infection. The sets of diagnoses used to determine eligibility and calculate the outcomes were similar to those we reported previously [11].

**Secondary outcomes**

Secondary outcomes included the rates of oral antibiotic prescribing for three other groups of qualifying visits: 1) visits with diagnoses for potentially-antibiotic-appropriate ARI diagnoses (acute sinusitis and acute pharyngitis; Additional file 1: Table S1); 2) visits with diagnoses also potentially indicating an ARI (e.g., pneumonia, cough; Additional file 1: Table S1); and 3) the rate of antibiotic prescribing for the sum of visits
included in the primary outcome and these two secondary outcomes (all diagnosis categories combined). We applied the same additional inclusion and exclusion criteria above to these secondary diagnoses as we did to the primary outcome. We examined the distribution of visits in each of these 3 categories during the intervention year and the year prior to look for “diagnosis shifting” through which clinicians could be more likely to select antibiotic-appropriate diagnoses to conceal an unchanged overall antibiotic prescribing rate.

Safety monitoring
In order to ensure that interventions did not cause inappropriate under-prescribing of antibiotics, we examined the records of all patients who had return visits with a diagnosis indicative of a bacterial respiratory tract infection within 30 days of a qualifying visit for a non-antibiotic-appropriate diagnosis, a potentially-antibiotic-appropriate diagnosis, or cough. In cases where an antibiotic was not prescribed at the index visit, a physician (SDP) blinded to clinician intervention group judged whether: 1) an antibiotic was prescribed within 24 h without the patient having to reinitiate contact (e.g. physician called the patient and prescribed an antibiotic in response to an abnormal chest x-ray), 2) an antibiotic was not prescribed and it seemed unlikely that an antibiotic at the index visit would have improved the clinical course, or 3) an antibiotic was not prescribed and it may have been clinically useful had an antibiotic been prescribed. An independent data safety and monitoring board reviewed this data during the study.

Statistical analysis
The effects of the study interventions were assessed using separate mixed logistic regression models for each of the primary and secondary outcomes that included each of the three interventions and clinicians’ prior prescribing rate as fixed effects, and individual clinicians as random effects (PROC GLIMMIX, SAS 9.3). We tested models with and without two-way and three-way interaction terms between the interventions. Because including these interaction terms had very little impact on the estimated effects of the interventions and complicate the interpretation of the results, we report results of models without interaction terms. Because this was intended as a pilot study, no formal power analysis was conducted. Results are provided with 95 % confidence intervals.

In addition to the primary planned analyses, post hoc we constructed models for each of the primary and secondary outcomes that included eligible visits during the year prior to and the year during the intervention period. We tested models that included a term for the intervention year and also a continuous variable for time to assess for evidence of temporal changes in antibiotic prescribing rates.

We performed post hoc analyses that included data from the 10 physicians working in the same practice who did not participate in the randomized trial during the year prior to and the year during the intervention period to determine if their antibiotic prescribing rates during these two years differed significantly from the clinicians who participated in the study.

Results
Of the 37 internists and 1 nurse practitioner approached, 27 internists and the nurse practitioner enrolled in the trial (74 %). Participating clinicians were 39 male, 61 white, 36 Asian and 4 % African American. Most (75 %) were over 40 years of age. The average number (standard deviation) of distinct patients seen by a participating clinician was 905 (483) in the pre-intervention year and 923 (543) in the intervention year. The flow of participants through the trial is shown in the Additional file 2: Figure S1. Of all visits made to participating clinicians in the pre-intervention year, 7.2 % were eligible ARI visits analyzed for any of the study outcomes. In the intervention year 7.7 % were eligible ARI visits. Patients’ demographic characteristics are provided in Table 1.

The number of clinicians randomized to the different intervention assignments is shown in Table 2 along with the number of eligible study visits with a non-antibiotic-appropriate ARI diagnosis during the year prior to the study and the year during the study. Additional details of are provided in the study flow diagram (Additional file 2: Figure S1). Participating physicians prescribed antibiotics in 24.7 % of visits for non-antibiotic-appropriate ARI diagnoses in the year prior to the trial and in 5.2 % of such visits during the year of the trial (Table 2). Corresponding results for the secondary outcomes are provided in Additional file 1: TablesS2, S3 and S4. None of the three interventions significantly lowered (or raised) rates of antibiotic prescribing for visits with non-antibiotic-appropriate diagnoses (Table 3). However, for visits with other ARI diagnoses and symptoms, the Suggested Alternatives intervention was associated with significantly lower odds of antibiotic prescribing (odds ratio [OR], 0.62; 95 % confidence interval [CI], 0.44–0.89). The Suggested Alternatives and Peer Comparisons interventions were associated with lower odds of antibiotic prescribing for the all ARI diagnoses combined—OR 0.72 (CI 0.54–0.96) and OR 0.73 (CI 0.53–0.995), respectively. The clinician’s prescribing rate in the pre-trial year was strongly associated with the antibiotic prescribing rate during the trial year for each outcome examined (Table 3).

Table 4 shows the distribution of eligible visits among the three different diagnosis categories we examined in
the pre-trial year and the trial year. There were similar total numbers of eligible study visits in each year (3276 in the pre-trial year and 3099 in the trial year). There was no suggestion of diagnosis shifting in the selection of diagnosis codes during the study.

In the mixed regression models, antibiotic prescribing was substantially and significantly lower during the intervention year compared to the pre-intervention year across all categories, and the continuous variable for time (study quarter, used to assess for an underlying temporal trend in antibiotic prescribing) was not significant in any of the four models examined except for a slight increase in prescribing rate over time for possibly-antibiotic-

| Table 1 Demographic characteristics of patients seen by participating clinicians |
|---------------------------------------------------------------|------------------|--------------------------|
| | All Patients | Patients Included in Study Analyses |
|---------------------------------------------------------------|------------------|--------------------------|
| Age, mean (SD) | Pre-intervention | Intervention | Pre-intervention | Intervention |
| 48.7 (16.7) | 49.4 (16.9) | 46.6 (16.2) | 47.7 (16.3) |
| Sex, n (%) |                      |                |                      |                |
| Male | 7269 (36.2) | 7469 (36.6) | 904 (32.2) | 888 (33.1) |
| Female | 12798 (63.8) | 12950 (63.4) | 1907 (67.8) | 1791 (66.9) |
| Race/Ethnicity, n (%) |                |                |                      |                |
| White, non-Hispanic | 9460 (47.1) | 9659 (47.3) | 1384 (49.2) | 1244 (46.4) |
| Black | 3706 (18.5) | 3806 (18.6) | 422 (15) | 444 (16.6) |
| Hispanic | 1380 (6.9) | 1457 (7.1) | 201 (7.2) | 204 (7.6) |
| Asian | 974 (4.9) | 1056 (5.2) | 121 (4.3) | 129 (4.8) |
| American Indian/Pacific Islander | 42 (0.2) | 50 (0.2) | 11 (0.4) | 9 (0.3) |
| More than one race | 359 (1.8) | 414 (2) | 52 (1.8) | 58 (2.2) |
| Other | 1481 (7.4) | 1524 (7.5) | 213 (7.6) | 225 (8.4) |
| Unknown | 2665 (13.3) | 2453 (12) | 407 (14.5) | 366 (13.7) |

| Table 2 Results of clinician randomization and the primary outcome |
|---------------------------------------------------------------|------------------|--------------------------|
| Intervention | Randomized Clinicians (n) | Antibiotic Prescribing for Visits with Non-Antibiotic-Appropriate ARI Diagnoses | Difference in Antibiotic Prescribing Rate between Intervention and Pre-intervention Period % (95 % CI) |
|---------------------------------------------------------------|------------------|--------------------------|
| No intervention | 4 | 7 / 57 (12.3) | 5 / 136 (3.4) | −86 (−179 to 0.7) |
| Accountable Justifications | 3 | 14 / 72 (19.4) | 8 / 70 (11.4) | −80 (−20.0 to 4.0) |
| Suggested Alternatives | 3 | 7 / 44 (15.9) | 4 / 51 (7.8) | −8.1 (−21.5 to 5.4) |
| Peer Comparisons | 3 | 31 / 74 (41.9) | 8 / 68 (11.8) | −30.1 (−44.0 to −16.3) |
| Accountable Justifications, Suggested Alternatives | 4 | 20 / 128 (15.6) | 2 / 95 (2.1) | −13.5 (−20.5 to −6.5) |
| Suggested Alternatives, Peer Comparisons | 4 | 41 / 118 (34.8) | 4 / 102 (3.9) | −30.8 (−40.3 to −21.3) |
| Accountable Justifications, Peer Comparisons | 4 | 44 / 187 (23.5) | 6 / 206 (2.9) | −20.6 (−27.2 to −14.1) |
| Accountable Justifications, Suggested Alternatives, Peer Comparisons | 3 | 46 / 171 (26.9) | 9 / 162 (5.6) | −21.4 (−28.9 to −13.8) |
| Any Accountable Justifications | 14 | 124 / 558 (22.2) | 25 / 532 (4.7) | −17.5 (−21.4 to −13.6) |
| No Accountable Justifications | 14 | 86 / 293 (29.4) | 21 / 357 (5.9) | −23.5 (−29.3 to −17.7) |
| Any Suggested Alternatives | 14 | 114 / 461 (24.7) | 19 / 410 (4.6) | −20.1 (−24.5 to −15.7) |
| No Suggested Alternatives | 14 | 96 / 390 (24.6) | 27 / 479 (5.6) | −19.0 (−23.7 to −14.2) |
| Any Peer Comparisons | 14 | 162 / 550 (29.5) | 27 / 537 (5.0) | −24.4 (−28.7 to −20.2) |
| No Peer Comparisons | 14 | 48 / 301 (15.9) | 19 / 352 (5.4) | −10.6 (−15.3 to −5.8) |
| All groups combined | 28 | 210 / 851 (24.7) | 46 / 889 (5.2) | −19.5 (−22.8 to −16.3) |

ARI acute respiratory infection, CI confidence interval
appropriate diagnoses (odds ratio [OR] per calendar quarter: 1.11 [1.03–1.20]; Table 5; Fig. 1).

In the post hoc analysis, non-participating physicians prescribed antibiotics in 35.3 % of visits for non-antibiotic-appropriate ARI diagnoses in the year prior to the trial and in 28.6 % of such visits during the year of the trial. For all ARI diagnoses combined, prescribing rates for non-participants during these two years were 49.6 % and 46.2 %, respectively. In multivariable regression models, non-participants’ prescribing rates were not significantly different from those of study participants during the year prior to the intervention but were significantly higher than study participants during the trial period. The OR for prescribing antibiotics for non-antibiotic-appropriate ARI visits during the trial period for non-participants compared to participants was 4.99 (2.35–10.6), and for all ARI diagnoses combined OR 1.70 (1.23–2.36).

In the safety monitoring analyses, we analyzed 18 return visits (0.74 %) with a diagnosis of a bacterial respiratory tract infection that occurred within 30 days of a qualifying visit at which an antibiotic was not prescribed. Of these, 7 of these received antibiotics within 24 h of the qualifying visit without the patient having to reinitiate contact. In 3 cases, it seemed unlikely that an antibiotic would have improved the course of illness if prescribed at the initial visit. In 8 cases (0.31 %), an antibiotic was not prescribed and may have been clinically useful had it been prescribed at the index visit. None of these 8 patients died or had a prolonged hospitalization. These visits were evenly distributed across the intervention groups (Additional file 1: Table S5).

**Discussion**

This pilot study tested three interventions drawing on social psychology and behavioral economic principles. This initial test of these interventions helped inform the conduct of a larger, multi-site trial [16], and also led to several interesting observations. The study resulted in large reductions in antibiotic prescribing at adult outpatient visits for acute respiratory infections in a large primary care practice compared to the year before the study began.

### Table 3  Intervention effects on primary and secondary outcomes

| Intervention | Accountable justifications | Suggested alternatives | Peer comparisons | Clinician’s prior year prescribing rate (per 10 % increase) |
|--------------|---------------------------|------------------------|-----------------|----------------------------------------------------------|
| Antibiotic for non-antibiotic appropriate ARI diagnoses (primary outcome) | 0.98 (0.42–2.29) | 0.68 (0.29–1.58) | 0.45 (0.18–1.11) | 1.57 (1.15–2.13) |
| Antibiotic for potentially antibiotic appropriate ARI diagnoses | 0.77 (0.42–1.41) | 0.57 (0.31–1.05) | 1.14 (0.59–2.19) | 1.71 (1.23–2.36) |
| Antibiotic for other ARIs diagnoses or symptoms of interest | 1.29 (0.92–1.80) | 0.62 (0.44–0.89) | 0.70 (0.48–1.02) | 1.40 (1.25–1.57) |
| Antibiotic for all three combined | 1.05 (0.80–1.39) | 0.72 (0.54–0.96) | 0.73 (0.53–0.995) | 1.64 (1.45–1.84) |

*RI acute respiratory infection

\( * p < .005 \)
\( ** p < .01 \)
\( *** p < .001 \)
\( **** p < 0.05 \)

### Table 4  Antibiotic prescribing for eligible visits with all potential ARI diagnoses, pre-intervention year and intervention year

| Diagnosis Category | Year prior to intervention | Intervention year |
|--------------------|----------------------------|------------------|
|                    | % of ARI visits in diagnosis category | Number visits given antibiotic | Number eligible visits | Percentage prescribed antibiotic | % of ARI visits in diagnosis category | Number visits given antibiotic | Number eligible visits | Percentage prescribed antibiotic |
| Non-Antibiotic Appropriate ARI Diagnoses | 26.0 | 210 | 851 | 24.7 | 28.7 | 46 | 889 | 5.2 |
| Potentially Antibiotic Appropriate ARI Diagnoses | 24.9 | 411 | 817 | 50.3 | 24.3 | 336 | 752 | 44.7 |
| Other ARIs Diagnoses or Symptoms of Interest | 49.1 | 646 | 1608 | 40.2 | 47.0 | 369 | 1458 | 25.3 |
| All diagnoses combined | 100 | 1267 | 3276 | 38.7 | 100 | 751 | 3099 | 24.2 |
Reductions in antibiotic prescribing occurred both for clinicians receiving one or more active interventions and those assigned to the control condition (but not among physicians who declined to participate). The decline in prescribing occurred in all diagnosis categories examined and was most dramatic for visits with non-antibiotic-appropriate diagnoses (a decline of 19.5%). During the intervention year, receipt of our interventions did not significantly affect antibiotic prescribing at visits with non-antibiotic-appropriate diagnoses. Two of the interventions, Suggested Alternatives and Peer Comparisons, yielded significantly lower rates of antibiotic prescribing for the secondary outcome of all the diagnostic categories combined. Compared to our larger, clinic-randomized trial, the overall reduction in antibiotic prescribing observed here was similar. Notable differences between that study and the one presented here are that in the larger study—which had greater statistical power—accountable justifications and peer comparisons led to significantly greater reductions in antibiotic prescribing at non-antibiotic-appropriate ARI visits [16].

The magnitude of the reduction in antibiotic prescribing observed from the pre-study year to the study year was larger than what has generally been observed in prior studies aimed at reducing antibiotic prescribing in ARIs. For instance, Gonzales and colleagues recently observed 12 to 13% declines in antibiotic prescribing for acute bronchitis at intervention sites given computerized or printed decision support for acute cough illnesses and a small increase in antibiotic prescribing at control sites [9]. Likewise, a systematic review of quality improvement interventions aimed at reducing inappropriate antibiotic use showed a median reduction in antibiotic prescribing of 9.7% (interquartile range 6.6—13.7%) [7].

There are several possible explanations for our observed findings of a large overall decline in prescribing with little observable intervention-specific effects. First, clinicians’ enrollment in the study, completion of the on-line educational module, receipt of a financial incentive to participate in the study, and awareness that they were among a small group having their antibiotic prescribing practices scrutinized may have given rise to a fairly strong observer effect (or Hawthorne effect) even among clinicians assigned to the control condition [32]. This phenomenon has been described among pediatricians who had their antibiotic prescribing behavior observed [33]. In fact, we expected the Peer Comparison and Accountable Justifications interventions to operate partly through participants’ sensitivity to being observed by others. Physicians within this practice were accustomed to having their performance measured for a variety of clinical topics for quality improvement purposes [34], and the observer effect may have been particularly strong. Because the antibiotic prescribing rate among this clinician group prior to the intervention year was already lower than what has been reported in other studies [1, 2, 7], the prescribing rate for the primary outcome may have reached a floor so that adding additional interventions could not reduce it further.

### Table 5 Results of mixed effects models pre-intervention year and intervention year

| Diagnosis Category | Year prior to the intervention | Calendar quarter |
|--------------------|-------------------------------|-----------------|
| Antibiotic for non-antibiotic appropriate ARI diagnoses | Odds Ratios (95% confidence Intervals) | 1.01 (0.90–1.14) |
| Antibiotic for potentially-antibiotic-appropriate ARI diagnoses | 2.40 (1.69–3.42) | 1.11 (1.03–1.20)** |
| Antibiotic for other ARIs diagnoses or symptoms of interest | 1.59 (1.10–2.29)** | 0.98 (0.90–1.06) |
| Antibiotic for all three combined | 2.28 (1.83–2.83)** | 1.03 (0.98–1.08) |

ARI: acute respiratory infection

* $p < 0.001$

** $p < 0.05$

*Models predicting antibiotic prescribing include a pre-intervention year variable and a continuous variable for calendar quarter as fixed effects, and clinician as random effects. Analyses are exploratory.

Fig. 1 Percentage of eligible visits with antibiotic prescribed for visits with non-antibiotic appropriate diagnoses and all ARI diagnosis categories combined by quarter. (Black Square) All eligible visits for acute respiratory infections. (Gray Diamond) Eligible visits for non-antibiotic-appropriate acute respiratory infections. Error bars represent 95% confidence intervals. ARI: acute respiratory infection

Fig. 2 Percentage of eligible visits with antibiotic prescribed for visits with non-antibiotic appropriate diagnoses and all ARI diagnosis categories combined by quarter. (Black Square) All eligible visits for acute respiratory infections. (Gray Diamond) Eligible visits for non-antibiotic-appropriate acute respiratory infections. Error bars represent 95% confidence intervals. ARI: acute respiratory infection
Second, contamination from working in close proximity to peers who received single or multiple interventions related to antibiotic prescribing may have led clinicians to reduce their prescribing more than they otherwise would have. For example, learning that his colleague was a “top performer” relative to a group that includes his own performance may have instilled a sense of competition in a control participant. Such informational contamination between conditions could have been due to information concerning interventions, information about antibiotic prescription rates and/or general conversation about antibiotic over-prescribing. The fact that prescribing rates among non-participating physicians within the same physical practice changed little and remained substantially greater than rates for study participants speaks against this possibility.

Third, this study is limited by its sample size. This was a fairly small pilot study meant to test procedures to be employed in a larger multisite study [11]. The number of eligible visits for the primary outcome was insufficient to exclude clinically meaningful intervention effects on the primary study outcome. Furthermore, because we were testing the factorial design that was to be used in the subsequent larger trial, there were only three or four clinicians within each intervention assignment and only four clinicians who received none of the interventions. The small sample sizes probably account for highly variable baseline antibiotic prescribing rates between groups. Despite lack of statistical significance, we observed the expected direction of effects, and the magnitude of effects in the Suggested Alternatives and Peer Comparison interventions are promising.

Consistent with prior studies [10, 35, 36], we did not observe any evidence that clinicians manipulated their diagnostic coding away from non-antibiotic-appropriate diagnoses toward those that would appear to more readily justify the use of antibiotic or those that would not trigger the clinical decision support interventions. This provides reassurance that the changes in antibiotic prescribing rates that we observed were real, and not merely caused by changes in diagnosis selection.

We also observed a reduction in antibiotic prescribing at potentially-antibiotic-appropriate ARI visits (which consist of acute sinusitis and pharyngitis). These clinical syndromes are frequently caused by viruses, and our safety analysis showed very few patients returning within 30 days following a visit where an antibiotic was not prescribed and it may have been clinically useful had one been given. Therefore, we think it is likely that the reduction in antibiotic use in this diagnostic category was clinically appropriate.

An additional potential limitation is worth noting. The baseline antibiotic prescribing rates among clinicians in this group (both among clinicians who participated and those who didn’t) were lower than what has been reported in broader populations of clinicians [1–3]. This suggests that these findings may not be generalizable to other practice settings.

Conclusions
The conduct of this pilot study had a large impact on antibiotic prescribing across all study physicians, including among control participants (but not among non-participants within the same practice). The results of a larger multisite trial conducted by this same study group help address this study’s aforementioned limitations [16]. The large reductions in antibiotic prescribing we observed even among control participants are interesting and suggest that interventions designed with an intentional observer effect could be particularly effective.

Additional files

Additional file 1: Table S1. Acute Respiratory Infection Diagnoses Related to Interventions and Outcomes Assessments. Table S2. Results of Clinician Randomization and the Secondary Outcome Potentially-Antibiotic-Appropriate ARI Diagnoses. Table S3. Results of Clinician Randomization and the Secondary Outcome Other ARI Diagnoses or Symptoms of Interest. Table S4. Results of Clinician Randomization and the Secondary Outcome All ARI Categories Combined. Table S5. Distribution of Safety Monitoring Events. (DOCX 27 kb)

Additional file 2: Study Flow Diagram. (PPTX 77 kb)

Abbreviations
ARI, acute respiratory infection; CI, confidence interval; EHR, electronic health record; NMFF, Northwestern Medical Faculty Foundation; OR, odds ratio

Acknowledgements
We would like to thank the clinicians who participated in this study.

Funding
National Institutes of Health, National Institute on Aging, grant 1RC4AG039115-01. The funding organization had no role in the collection of data, its analysis and interpretation, or the decision to approve or disapprove publication of the finished manuscript.

Availability of data and materials
Due to the small number of participating clinicians and the potential for subject identification, data is not shared.

Authors’ contributions
JND, CRF, DM, MWF, JAL and SDP conceived the study. JND, SDP, MWF, DM, JAL, CRF, NJG, EF, and AC participated in the design and/or implementation of study procedures. SDP drafted the manuscript. JND, DM, MWF, JAL, CRF, NJG, EF, and AC participated in critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Competing interests
Dr. Persell receives unrelated research grant support from Pfizer, Inc. There are no other potential competing interests to report.

Consent for publication
Not applicable.
Ethics approval and consent to participate
The institutional review boards of Northwestern University and the University of Southern California approved the study. Participating clinicians provided written informed consent.

Author details
1Division of General Internal Medicine and Geriatrics, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL 60611, USA. 2Center for Primary Care Innovation, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, 10th Floor, Chicago, IL 60611, USA. 3USC Schaeffer Center for Health Policy and Economics, University of Southern California, 3335 S. Figueroa Street, Unit A, Los Angeles, CA 90089-7273, USA. 4Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital; Harvard Medical School, 1620 Tremont Street, BC-3-2X, Boston, MA 02120, USA. 5RAND, 20 Park Plaza, Suite 920, Boston, MA 02116, USA. 6RAND, 1776 Main St, Santa Monica, CA 90401, USA. 7Department of Pharmacy, UCLA Anderson School of Management; David Geffen School of Medicine at UCLA, UCLA, 110 Westwood Plaza D-511, Los Angeles, CA 90095, USA.

Received: 27 August 2015 Accepted: 13 July 2016
Published online: 05 August 2016

References
1. Barnett ML, Linder JA. Antibiotic prescribing for adults with acute bronchitis in the United States, 1996–2010. JAMA. 2014;311:2020–2.
2. Barnett ML, Linder JA. Antibiotic prescribing to adults with sore throat in the United States, 1997–2010. JAMA Intern Med. 2014;174:138–40.
3. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009;302:758–66.
4. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed 28 Jul 2015.
5. Shehab N, Patel PR, Srinivasan A, et al. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008;47:735–43.
6. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579–87.
7. Ranji SR, Steinman MA, Shojania KG, et al. Interventions to reduce unnecessary antibiotic prescribing: a systematic review and quantitative analysis. Med Care. 2008;46:847–62.
8. Linder JA. Antibiotic Prescribing for acute respiratory infections–success that’s way off the mark: comment on “A cluster randomized trial of decision support strategies for reducing antibiotic use in acute bronchitis”. JAMA Intern Med. 2013;173:273–5.
9. Gonzales R, Anderer T, McCulloch CE, et al. A cluster randomized trial of decision support strategies for reducing antibiotic use in acute bronchitis. JAMA Intern Med. 2013;173:267–73.
10. Gonzales R, Steiner JF, Lum A, et al. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA. 1999;281:1512–9.
11. Persell SD, Friedberg MW, Meeker D, et al. Use of behavioral economics and social psychology to improve treatment of acute respiratory infections (BEAR): rationale and design of a cluster randomized controlled trial [IRCA0039115-01]–study protocol and baseline practice and provider characteristics. BMC Infect Dis. 2013;13:290.
12. Calidini RB. Influence: Science and Practice. 4th ed. Needham Heights: Allyn & Bacon; 2001.
13. Dellavigna S, Dellavigna S. Psychology and economics evidence from the field. J Econ Lit. 2009;47:315–72.
14. Kahneman D, Tversky A. Choices, values and frames. Cambridge: Cambridge University Press; 2000.
15. Gilovich T, Griffin D, Kahneman D, editors. Heuristics and biases: the psychology of intuitive judgment. Cambridge: Cambridge University Press; 2002.
16. Meeker D, Linder JA, Fox CR, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial. JAMA. 2016;315:562–70.
17. Gonzales R, Bartlett JG, Besier RE, et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Intern Med. 2001;134:521–9.
18. Hickner JM, Bartlett JG, Besier RE, et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med. 2001;134:496–505.
19. Cooper RJ, Hoffman JR, Bartlett JG, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med. 2001;134:509–17.
20. Gonzales R, Bartlett JG, Besier RE, et al. Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults: background. Ann Intern Med. 2001;134:490–4.
21. Lerner JS, Tetlock PE. Accounting for the effects of accountability. Psychol Bull. 1999;125:255–75.
22. Baumeister RE, Hutton DG. Self-presentation theory: self-construction and audience pleading. In: Mullen B, Goethals G, editors. Theories of group behavior. New York: Springer Verlag; 1987. p. 71–87.
23. Jereid T, Rosen B. Effects of opportunity to communicate and visibility of individual decisions on behavior in the common interest. J Appl Psychol. 1974;59:712–6.
24. Milinski M, Semmann D, Krambeck HJ. Reputations helps solve the “tragedy of the commons”. Nature. 2002;415:424–6.
25. Calidini R, Reno R, Kallgren C. A focus theory of normative conduct: recycling the concept of norms to reduce littering in public places. J Pers Soc Psychol. 1990;58:1015–26.
26. De Cremer D, Barker M. Accountability and cooperation in social dilemmas: the influence of others’ reputational concerns. Curr Psychol. 2003;22:155–63.
27. Grice H. Some further notes on logic and conversation. Cambridge: Harvard University Press; 1978.
28. Goldstein N, Calidini R, Griskevicius V. A room with a viewpoint: using social norms to motivate environmental conservation in hotels. J Consumer Res. 2008;35:472–82.
29. Kiefe C, Allison JJ, Williams OD, Person SD, Weaver MT, Weissman NW. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. JAMA. 2001;285:2871–9.
30. Schultz PW, Nolan JM, Calidini RB, Goldstein NJ, Griskevicius V. The constructive, destructive, and reconstructive power of social norms. Psychol Sci. 2007;18:429–34.
31. Box GE, Hunter JS. The 2 k–p fractional factorial designs. Technometrics. 1961;3:511–1.
32. Parsons HM. What Happened at Hawthorne? New evidence suggests the Hawthorne effect resulted from operant reinforcement contingencies. Science. 1974;183:922–32.
33. Mangione-Smith R, Elliott MN, McDonald L, et al. An observational study of antibiotic prescribing behavior and the Hawthorne effect. Health Serv Res. 2002;37:1603–23.
34. Persell SD, Kaiser D, Dolan NC, et al. Changes in performance after implementation of a multifaceted electronic-health-record-based quality improvement system. Med Care. 2011;49:117–5.
35. Metlay JP, Camargo Jr CA, Mackenzie T, et al. Cluster-randomized trial to improve antibiotic use for adults with acute respiratory infections treated in emergency departments. Ann Emerg Med. 2007;50:221–30.
36. Harris RH, Mackenzie TD, Leeman-Castillo B, et al. Optimizing antibiotic prescribing for acute respiratory tract infections in an urban urgent care clinic. J Gen Intern Med. 2003;18:326–34.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research
Submit your manuscript at www.biomedcentral.com/submit